We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ ...
Bristol Myers BMY is banking on its growth portfolio, which comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others, to drive top-line ...
Alliance Global Partners analyst Scott Henry maintained a Buy rating on Quantum-Si today and set a price target of $2.50. The company’s shares closed last Tuesday at $0.95, close to its 52-week low of ...
These stocks can be slow-and-steady wealth compounders.
Major pharma companies are pressed by Senate Democrats regarding details on savings to the Medicaid program from Trump's drug pricing deals. Read more here.
Bristol-Myers Squibb offers a 4%+ dividend yield backed by steady payout growth and strong cash flow, making it one of the more attractive income stocks in the healthcare sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results